Dennis Burton

Summary

Affiliation: The Scripps Research Institute
Country: USA

Publications

  1. pmc A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120
    Emma T Crooks
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, USA
    Virology 366:245-62. 2007
  2. pmc Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
    Ann J Hessell
    Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA
    PLoS Pathog 5:e1000433. 2009
  3. pmc Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
    Leopold Kong
    Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA
    Nat Struct Mol Biol 20:796-803. 2013
  4. pmc The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies
    Devin Sok
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America Scripps Center for HIV AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 9:e1003754. 2013
  5. pmc A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 6:e1001028. 2010
  6. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
  7. pmc A Blueprint for HIV Vaccine Discovery
    Dennis R Burton
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    Cell Host Microbe 12:396-407. 2012
  8. pmc Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses
    Dennis R Burton
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 337:183-6. 2012
  9. pmc PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4
    Emilia Falkowska
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA
    J Virol 86:4394-403. 2012
  10. pmc Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120
    James M Binley
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego CA 92121, USA
    Retrovirology 3:39. 2006

Detail Information

Publications102 found, 100 shown here

  1. pmc A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120
    Emma T Crooks
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, USA
    Virology 366:245-62. 2007
    ..Therefore, to make progress toward a more effective VLP-based vaccine, we will need to find ways to refocus the attention of B cells on native trimers...
  2. pmc Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
    Ann J Hessell
    Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA
    PLoS Pathog 5:e1000433. 2009
    ..The results raise the possibility that some epitopes on HIV may be better vaccine targets than others and support targeting the glycan shield of the envelope...
  3. pmc Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
    Leopold Kong
    Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA
    Nat Struct Mol Biol 20:796-803. 2013
    ....
  4. pmc The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies
    Devin Sok
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America Scripps Center for HIV AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 9:e1003754. 2013
    ..Finally, patterns of neutralization of inferred bnAb intermediates suggest hypotheses as to how SHM may lead to potent and broad HIV neutralization and provide important clues for immunogen design. ..
  5. pmc A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 6:e1001028. 2010
    ..In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera...
  6. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
    ....
  7. pmc A Blueprint for HIV Vaccine Discovery
    Dennis R Burton
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    Cell Host Microbe 12:396-407. 2012
    ..The synthesis of rational immunogen design and immunization strategies, together with iterative improvements, offers great promise for advancing toward an HIV vaccine...
  8. pmc Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses
    Dennis R Burton
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Science 337:183-6. 2012
    ..Molecular characterizations of the antibodies and, most importantly, of the sites of vulnerability that they recognize give hope for the discovery of new vaccines and drugs...
  9. pmc PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4
    Emilia Falkowska
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA
    J Virol 86:4394-403. 2012
    ....
  10. pmc Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120
    James M Binley
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego CA 92121, USA
    Retrovirology 3:39. 2006
    ....
  11. pmc Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors
    Paul J Peters
    Center for AIDS Research, Program in Molecular Medicine and Department of Molecular Genetics and Microbiology, 373 Plantation Street, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Retrovirology 5:5. 2008
    ..These R5 envelopes conferred a wide range of macrophage tropism and included highly macrophage-tropic variants from brain and non-macrophage-tropic variants from lymph node...
  12. ncbi request reprint Antibodies, viruses and vaccines
    Dennis R Burton
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Rev Immunol 2:706-13. 2002
    ..Several viruses, such as HIV, have evolved mechanisms to evade neutralizing-antibody responses, and these viruses present special challenges for vaccine design that are now being tackled...
  13. pmc Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
    Dennis R Burton
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 108:11181-6. 2011
    ..A nonneutralizing antibody to gp41 may have a limited capacity to protect, but the results suggest that the central focus of HIV-1 vaccine research should be on the induction of potently neutralizing antibodies...
  14. ncbi request reprint Immunology. Sugar determines antibody activity
    Dennis R Burton
    Department of Immunology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 313:627-8. 2006
  15. pmc A vaccine for HIV type 1: the antibody perspective
    D R Burton
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 94:10018-23. 1997
    ..Vaccine design should focus on presentation of an intact mature oligomer, increasing the immunogenicity of the oligomer and learning from the antibodies available that potently neutralize primary viruses...
  16. ncbi request reprint Immunology. Square-dancing antibodies
    Dennis R Burton
    Department of Immunology, Skaggs Institute for Chemical Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 317:1507-8. 2007
  17. ncbi request reprint Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?
    D R Burton
    Department of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Nat Med 6:123-5. 2000
    ..However, newer data show that antibodies can protect against infection with these pathogens, and new methods to elicit production of functional antibodies should be sought...
  18. pmc Antibody vs. HIV in a clash of evolutionary titans
    Dennis R Burton
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 102:14943-8. 2005
    ..Antibodies, like HIV, can evolve relatively rapidly through mutation and selection. It seems that the structures of these broadly neutralizing antibodies bear witness to a heroic struggle between two titans of rapid evolution...
  19. ncbi request reprint Phage display
    D R Burton
    Department of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, CA 92037, USA
    Immunotechnology 1:87-94. 1995
    ....
  20. ncbi request reprint HIV vaccine design and the neutralizing antibody problem
    Dennis R Burton
    Departments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California, USA
    Nat Immunol 5:233-6. 2004
  21. ncbi request reprint Antibody domain exchange is an immunological solution to carbohydrate cluster recognition
    Daniel A Calarese
    Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 300:2065-71. 2003
    ..The unique interdigitation of Fab domains within an antibody uncovers a previously unappreciated mechanism for high-affinity recognition of carbohydrate or other repeating epitopes on cell or microbial surfaces...
  22. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  23. pmc Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:642-58. 2003
    ..These reengineered gp120s are prospective immunogens that may prove capable of eliciting broadly neutralizing antibodies...
  24. pmc Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
    Amandeep K Dhillon
    The Scripps Research Institute, Department of Immunology IMM 2, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 81:6548-62. 2007
    ..The most likely epitope recognized by the monomeric gp120 binding neutralizing fraction is the CD4 binding site, although other epitopes, such as the glycan shield, cannot be excluded...
  25. pmc Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization
    Christian H Bell
    Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Mol Biol 375:969-78. 2008
    ..The structure helps explain how B4e8 can tolerate a certain degree of sequence variation within V3 and, hence, is able to neutralize an appreciable number of different HIV-1 isolates...
  26. pmc A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12
    Michael B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:6965-78. 2003
    ..The results suggest a model in which antibody access to the CD4bs on the envelope spike of HIV-1 is restricted by the orientation and/or dynamics of the V1/V2 and V3 loops, and b12 avoids these restrictions...
  27. pmc Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
    Katie J Doores
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 107:13800-5. 2010
    ..This study revises and extends our understanding of the glycan shield of HIV with implications for AIDS vaccine design...
  28. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    ..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
  29. pmc Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics
    Josh D Nelson
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Virology 377:170-83. 2008
    ..Nevertheless, the mAb panel may be useful as tools for elucidating access restrictions to the NHR of gp41 and in designing potential improvements to mimetics of receptor-activated Env...
  30. pmc Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:5889-901. 2003
    ..The hyperglycosylated mutant and its analogues described here are novel antigens that may provide a new approach to eliciting antibodies with b12-like neutralizing properties...
  31. pmc Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1
    Aran F Labrijn
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:10557-65. 2003
    ..The results identify hurdles in using CD4i epitopes as targets for antibody-mediated neutralization in vaccine design but also indicate that the CD4i regions could be efficiently targeted by small molecule entry inhibitors...
  32. pmc Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120
    Michael B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:5863-76. 2003
    ..1, and the reactivity profile had many similarities but also significant differences from that observed for gp120. The paratope map of b12 may facilitate the design of molecules that are able to elicit b12-like activities...
  33. ncbi request reprint Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design
    Erica Ollmann Saphire
    Dept of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines, La Jolla, California 92037 USA
    Adv Exp Med Biol 535:55-66. 2003
  34. pmc Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes
    Maxime Moulard
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:6913-8. 2002
    ....
  35. pmc Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12
    Daniel A Calarese
    Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 102:13372-7. 2005
    ..These results have important consequences for the design of immunogens to elicit 2G12-like neutralizing antibodies as a component of an HIV vaccine...
  36. ncbi request reprint Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
    Rosa M F Cardoso
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Immunity 22:163-73. 2005
    ..These structural insights should assist in the design of immunogens to elicit 4E10-like neutralizing responses...
  37. pmc Comparing antigenicity and immunogenicity of engineered gp120
    Suganya Selvarajah
    The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 79:12148-63. 2005
    ..More precise focusing to a neutralizing epitope will likely require several iterations comparing antigenicity and immunogenicity of engineered proteins...
  38. pmc Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1
    Robert Pejchal
    Department of Molecular Biology, Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 107:11483-8. 2010
    ..Thus, PG9 and PG16 use unique structural features to mediate potent neutralization of HIV-1 that may be of utility in antibody engineering and for high-affinity recognition of a variety of therapeutic targets...
  39. ncbi request reprint Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity
    Erin M Scherer
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    AIDS 21:2131-9. 2007
    ..We used a number of assays to understand whether 2F5 and 4E10 are autoreactive, polyreactive, or have a generalized affinity for lipids that may facilitate recognition of their membrane proximal epitopes...
  40. pmc Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody
    Florence M Brunel
    epartments of Chemistry, The Scripps Research Institute, 10550 N Torrey Pines Rd, CVN 6, La Jolla, CA 92037, USA
    J Virol 80:1680-7. 2006
    ..Hence, this study represents the first stage toward iterative development of a vaccine based on the 4E10 epitope...
  41. ncbi request reprint Conformation of PrP(C) on the cell surface as probed by antibodies
    Estelle Leclerc
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Mol Biol 326:475-83. 2003
    ..The relative inaccessibility of the 13A5 epitope likely reflects either PrP(C)-PrP(C) interaction, interaction between PrP(C) and other constituents on the cell membrane, or the existence of PrP(C) subspecies with distinct conformations...
  42. ncbi request reprint Fc receptor but not complement binding is important in antibody protection against HIV
    Ann J Hessell
    Department of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 449:101-4. 2007
    ..Overall, the data suggest the potential importance of activity against both infected cells and free virus for effective protection against HIV...
  43. pmc Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor
    Jeffrey E Lee
    Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, Mail Drop IMM 2, La Jolla, California 92037, USA
    Nature 454:177-82. 2008
    ..This structure provides a template for unravelling the mechanism of EBOV GP-mediated fusion and for future immunotherapeutic development...
  44. ncbi request reprint Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody
    Hing Ken Lee
    Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Angew Chem Int Ed Engl 43:1000-3. 2004
  45. pmc A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies
    Robert Pejchal
    Department of Molecular Biology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 83:8451-62. 2009
    ....
  46. pmc A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120
    Rena D Astronomo
    The Scripps Research Institute, Department of Immunology and Microbial Science, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 82:6359-68. 2008
    ....
  47. pmc Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy
    Mansun Law
    The Scripps Research Institute, Department of Immunology IMM 2, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 81:4272-85. 2007
    ..ii) DNA vaccination with monomeric gp120-based antigens can elicit a consistent NAb response against the homologous neutralization-resistant virus by targeting epitopes outside the V1, V2, and V3 regions...
  48. pmc An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
    Josh D Nelson
    Department of Immunology, 10550 North Torrey Pines Road IMM 2, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 81:4033-43. 2007
    ....
  49. pmc Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein
    Jeffrey E Lee
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    Acta Crystallogr D Biol Crystallogr 65:1162-80. 2009
    ..Model building was assisted by the use of B-value-sharpened electron-density maps and the proper sequence register was confirmed by building alternate sequences using N-linked glycan sites as anchors and secondary-structural predictions...
  50. pmc Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions
    Erin M Scherer
    Department of Immunology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 107:1529-34. 2010
    ....
  51. pmc Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds
    Rena D Astronomo
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    Chem Biol 17:357-70. 2010
    ..The results presented reveal important design considerations for a carbohydrate-based vaccine component for HIV...
  52. ncbi request reprint Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs
    Klaus Koefoed
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Immunol Methods 297:187-201. 2005
    ..They exhibit high affinity for gp120, are directed against a variety of epitopes, but rarely exhibit the ability to neutralize HIV-1...
  53. pmc Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1
    Michael B Zwick
    Department of Immunology IMM 2, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 79:1252-61. 2005
    ..Neutralization experiments showing synergy between and T20 and 4E10 against HIV-1 are also presented. The data presented may aid in the design of antigens that better present the MPER of gp41 to the immune system...
  54. pmc Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
    Ann J Hessell
    Department of Immunology and Microbial Science and the International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 84:1302-13. 2010
    ..The study confirms the protective potential of 2F5 and 4E10 and supports emphasis on HIV immunogen design based on the MPER region of gp41...
  55. doi request reprint Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
    Ann J Hessell
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA
    Nat Med 15:951-4. 2009
    ..Overall, the results imply that lower amounts of antibody than previously considered protective may provide benefit in the context of typical human exposure to HIV-1...
  56. doi request reprint Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140
    Suganya Selvarajah
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    AIDS Res Hum Retroviruses 24:301-14. 2008
    ..However, the results also show that in order to elicit broadly neutralizing antibodies that target conserved epitopes, the soluble gp140 trimer immunogen template will require further modifications...
  57. pmc The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5
    Michael B Zwick
    Department of Immunology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 78:3155-61. 2004
    ..These observations present a challenge to vaccine strategies based on peptide mimics of the linear epitope...
  58. pmc Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions
    James M Binley
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:5678-84. 2003
    ..Overall, this disulfide-shackled virus is a unique tool with potential utility in vaccine design, drug discovery, and elucidation of the HIV-1 entry process...
  59. ncbi request reprint GP120: target for neutralizing HIV-1 antibodies
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    Annu Rev Immunol 24:739-69. 2006
    ..These include (a) the construction of mimics of the viral envelope spike and (b) the design of antigens specifically tailored to induce broadly neutralizing antibodies...
  60. pmc Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity
    Ralph Pantophlet
    The Scripps Research Institute, Department of Immunology and Microbial Science, IMM2, 10550 North Torrey Pines Road La Jolla, CA 92037, USA
    Virology 381:251-60. 2008
    ..Based on the data we propose an angle of interaction with V3 that is less stringent on access for antibodies with cross-neutralizing activity compared to antibodies that neutralize relatively fewer viruses...
  61. ncbi request reprint Public health. A sound rationale needed for phase III HIV-1 vaccine trials
    Dennis R Burton
    Scripps Research Institute, La Jolla, California, USA
    Science 303:316. 2004
  62. pmc Rational antibody-based HIV-1 vaccine design: current approaches and future directions
    Laura M Walker
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    Curr Opin Immunol 22:358-66. 2010
    ....
  63. ncbi request reprint Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Trends Mol Med 9:468-73. 2003
    ..This template-based approach to immunogen design shows promise as a means to engineer innovative AIDS vaccine candidates...
  64. ncbi request reprint HIV-1 neutralization: mechanisms and relevance to vaccine design
    Michael B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    Curr HIV Res 5:608-24. 2007
    ....
  65. pmc Printed covalent glycan array for ligand profiling of diverse glycan binding proteins
    Ola Blixt
    Glycan Synthesis and Protein Expression Core D, Consortium for Functional Glycomics, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 101:17033-8. 2004
    ....
  66. pmc Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
    James M Binley
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Virol 76:2606-16. 2002
    ..Coexpression of Env cleavage site mutants and furin is therefore a useful method for obtaining high-level expression of processed Env...
  67. ncbi request reprint Contrasting IgG structures reveal extreme asymmetry and flexibility
    Erica Ollmann Saphire
    Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Mol Biol 319:9-18. 2002
    ..The two separate hinges assume different conformations in order to accommodate the vastly different placements of the two Fab domains relative to the Fc domain. Interestingly, only one of two possible intra-hinge disulfides is formed...
  68. ncbi request reprint Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10
    Rosa M F Cardoso
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Mol Biol 365:1533-44. 2007
    ..Thus, the core 4E10 epitope was extended and modified to a WFX(I/L)(T/S)XX(L/I)W motif, where X does not play a major role in 4E10 binding and can be used to introduce helical-promoting constraints in the peptide epitope...
  69. pmc Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies
    Pascal Poignard
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:353-65. 2003
    ....
  70. pmc Total synthesis, revised structure, and biological evaluation of biyouyanagin A and analogues thereof
    K C Nicolaou
    Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    J Am Chem Soc 130:11114-21. 2008
    ..Biological investigations with the synthesized biyouyangagins A (2-11) and hyperolactones C (12-16) revealed that the activity of biyouyanagin A most likely resides in its hyperolactone C structural domain...
  71. pmc Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis
    Ralph Pantophlet
    The Scripps Research Institute, Department of Immunology, IMM2, La Jolla, CA 92037, USA
    Virology 364:441-53. 2007
    ....
  72. ncbi request reprint Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
    Mansun Law
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Med 14:25-7. 2008
    ..The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable...
  73. pmc Molecular analysis of the human autoantibody response to alpha-fodrin in Sjögren's syndrome reveals novel apoptosis-induced specificity
    Toshiaki Maruyama
    Department of Immunology, The Scripps Research Institute, La Jolla, California, USA
    Am J Pathol 165:53-61. 2004
    ..The anti-150-kd alpha-fodrin hmAbs may serve as valuable reagents for the study of SS pathogenesis and diagnostic analyses of SS salivary gland tissue...
  74. pmc Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies
    Erica Ollmann Saphire
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Mol Biol 369:696-709. 2007
    ....
  75. pmc Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc
    Gianluca Moroncini
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 101:10404-9. 2004
    ..PrPSc-specific antibodies produced by the approach described may find widespread application in the study of prion biology and replication and in the detection of infectious prions in human and animal materials...
  76. pmc Carbohydrate vaccines: developing sweet solutions to sticky situations?
    Rena D Astronomo
    Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Rev Drug Discov 9:308-24. 2010
    ..Here, we review the progress being made in addressing challenges posed by targeting the surface carbohydrates of bacteria, protozoa, helminths, viruses, fungi and cancer cells for vaccine purposes...
  77. ncbi request reprint Covalent display of oligosaccharide arrays in microtiter plates
    Marian C Bryan
    Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    J Am Chem Soc 126:8640-1. 2004
    ..The system was used to probe the multivalent interaction of 2G12 with an optimal epitope (Kd 0.1 muM)...
  78. pmc Synthesis and biological evaluation of 2',4'- and 3',4'-bridged nucleoside analogues
    K C Nicolaou
    Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Bioorg Med Chem 19:5648-69. 2011
    ..0 μM) and HxB2 (IC(50)=2.4 μM). These findings render bridged nucleosides as credible leads for drug discovery in the anti-HIV area of research...
  79. pmc A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV
    Brian Moldt
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 85:10572-81. 2011
    ..In future studies, these b12 variants will enable the investigation of the protective role of individual FcγRs in HIV infection...
  80. pmc Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities
    Welkin E Johnson
    New England Regional Primate Research Center, Department of Microbiology and Molecular Genetics, Harvard Medical School, One Pine Hill Drive, Box 9102, Southborough, MA 01772 9102, USA
    J Virol 77:9993-10003. 2003
    ..This reagent set and information should now be useful for defining the physical, structural, thermodynamic, and kinetic factors that influence relative sensitivity to antibody-mediated neutralization...
  81. pmc Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site
    Carolina Herrera
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Virol 77:1084-91. 2003
    ....
  82. ncbi request reprint HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
    Peter D Kwong
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 420:678-82. 2002
    ..Because this solution is available for cell-surface receptors but not for most antibodies, conformational masking enables HIV-1 to maintain receptor binding and simultaneously to resist neutralization...
  83. ncbi request reprint Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120
    Ronald S Veazey
    Tulane National Primate Research Center, Tulane University Health Sciences Center, Covington, Louisiana, USA
    Nat Med 9:343-6. 2003
    ..Lower amounts of b12 were less effective, suggesting that protection was dose dependent. These observations support the concept that viral entry inhibitors can help prevent the sexual transmission of HIV-1 to humans...
  84. ncbi request reprint Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120
    Hyeryun Choe
    Children s Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
    Cell 114:161-70. 2003
    ..These studies identify a distinct subset of CD4-induced HIV-1 neutralizing antibodies that closely emulate CCR5 and demonstrate that tyrosine sulfation can contribute to the potency and diversity of the human humoral response...
  85. pmc The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120
    Christopher N Scanlan
    The Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom
    J Virol 76:7306-21. 2002
    ....
  86. pmc Immune responses and HIV: a little order from the chaos
    DAVID H O'CONNOR
    University of Wisconsin Madison, Department of Pathology and Laboratory Medicine, Madison, WI 53711, USA
    J Exp Med 203:501-3. 2006
    ..We can't expect to predict details of the struggle between virus and immunity, right? Wrong--maybe we can make some predictions, say two new landmark studies with potentially huge consequences for AIDS vaccine design...
  87. pmc Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
    ..These data suggest that although effector T cells can limit viral replication, they are not able to assist humoral immunity to prevent the establishment of initial infection...
  88. ncbi request reprint The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus
    Gunilla B Karlsson Hedestam
    Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
    Nat Rev Microbiol 6:143-55. 2008
    ..Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens...
  89. pmc Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
    Penny L Moore
    Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA
    J Virol 80:2515-28. 2006
    ..We hypothesize that these nonfunctional forms of Env on particle surfaces serve to divert the antibody response, helping the virus to evade neutralization...
  90. ncbi request reprint Complete replication of hepatitis C virus in cell culture
    Brett D Lindenbach
    Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 309:623-6. 2005
    ..HCVcc replication was inhibited by interferon-alpha and by several HCV-specific antiviral compounds, suggesting that this in vitro system will aid in the search for improved antivirals...
  91. pmc Structural definition of a conserved neutralization epitope on HIV-1 gp120
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 445:732-7. 2007
    ..A site of vulnerability, related to a functional requirement for efficient association with CD4, can therefore be targeted by antibody to neutralize HIV-1...
  92. ncbi request reprint Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody
    Christopher N Scanlan
    Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford
    J Mol Biol 372:16-22. 2007
    ..Moreover, this study provides an alternative protein engineering approach to the design of a carbohydrate vaccine for HIV-1 by chemical synthesis...
  93. pmc Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region
    Nicholas J Mantis
    Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY 12208, USA
    J Immunol 179:3144-52. 2007
    ....
  94. pmc Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody
    Mei Yun Zhang
    Human Immunovirology Group, Laboratory of Experimental and Computational Biology, Center for Cancer Research, National Cancer Institute Frederick, NIH, Frederick, Maryland 21702 1201, USA
    J Virol 78:9233-42. 2004
    ....
  95. ncbi request reprint Urgently needed: a filter for the HIV-1 vaccine pipeline
    John P Moore
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA
    Nat Med 10:769-71. 2004
    ..Hence there is a need for assay standardization and for the creation of a centralized testing facility that could distribute consensus protocols and reagents...
  96. pmc A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120
    Alfredo Menendez
    Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada
    FASEB J 22:1380-92. 2008
    ..Moreover, 2G12.1 peptide is not an immunogenic mimic of the 2G12 epitope, since antisera produced against it did not bind gp120...
  97. ncbi request reprint Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions
    Alyssa C Biorn
    Department of Biochemistry, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, USA
    Biochemistry 43:1928-38. 2004
    ..More importantly, these results indicate that 12p1 binds to a unique site that may prove to be a prototypic target for novel CD4-gp120 inhibitors...
  98. ncbi request reprint Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope
    Ramalakshmi Darbha
    Macromolecular Crystallography Laboratory, National Cancer Institute, Frederick, Maryland 21702, USA
    Biochemistry 43:1410-7. 2004
    ..The X5 structure and fine mapping of its epitope may assist in the elucidation of the mechanisms of viral entry and neutralization, and the development of HIV-1 inhibitors and vaccines...
  99. ncbi request reprint gp41: HIV's shy protein
    Michael B Zwick
    Nat Med 10:133-4. 2004
  100. doi request reprint HIV vaccine research: the way forward
    Anthony S Fauci
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, 31 Center Drive, Bethesda, MD 20892, USA
    Science 321:530-2. 2008
    ..This article summarizes progress and challenges in HIV vaccine research, the priorities arising from a recent summit at NIAID, and the actions needed, some already under way, to address those priorities...
  101. ncbi request reprint The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12
    Christopher N Scanlan
    The Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom
    Adv Exp Med Biol 535:205-18. 2003

Research Grants40

  1. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2007
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. [unreadable] [unreadable] [unreadable]..
  2. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2007
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  3. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2006
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  4. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2006
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. [unreadable] [unreadable] [unreadable]..
  5. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2006
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. [unreadable] [unreadable] [unreadable]..
  6. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2005
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  7. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2005
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. ..
  8. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2005
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  9. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2007
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. [unreadable] [unreadable] [unreadable]..
  10. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2007
    ..There is widespread agreement that an HIV vaccine will need to trigger such a response to be fully effective. [unreadable] [unreadable] [unreadable]..
  11. THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN
    Dennis R Burton; Fiscal Year: 2010
    ..Such antibodies will be positioned for immediate clinical development as passive prophylactic agents for the prevention of HMPV disease in vulnerable patient cohorts. ..
  12. Probing the antibody response to HCV to facilitate rational immunogen design
    Dennis R Burton; Fiscal Year: 2010
    ..We propose to develop antibody-inducing vaccine candidates against HCV. A key feature of our work is the rational design of vaccine candidates based on countering some of the tricks that this virus uses to evade antibodies. ..
  13. THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN
    Dennis Burton; Fiscal Year: 2009
    ..Such antibodies will be positioned for immediate clinical development as passive prophylactic agents for the prevention of HMPV disease in vulnerable patient cohorts. ..
  14. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2009
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  15. Probing the antibody response to HCV to facilitate rational immunogen design
    Dennis Burton; Fiscal Year: 2009
    ..We propose to develop antibody-inducing vaccine candidates against HCV. A key feature of our work is the rational design of vaccine candidates based on countering some of the tricks that this virus uses to evade antibodies. ..
  16. THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN
    Dennis Burton; Fiscal Year: 2008
    ..Such antibodies will be positioned for immediate clinical development as passive prophylactic agents for the prevention of HMPV disease in vulnerable patient cohorts. ..
  17. Probing the germlines of broadly neutralizing anti-HIV antibodies in knockin mice
    Dennis Burton; Fiscal Year: 2008
    ..It is expected to generate valuable reagents and animals for the proposed UO1 consortium. ..
  18. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2008
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  19. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2005
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. ..
  20. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2004
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. ..
  21. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
    Dennis Burton; Fiscal Year: 2001
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  22. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2001
    DESCRIPTION: (Adapted from the Investigator's abstract): this is a new application from Dr. Dennis Burton to study the anti-viral activity of antibodies to a filovirus...
  23. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2000
    DESCRIPTION: (Adapted from the Investigator's abstract): this is a new application from Dr. Dennis Burton to study the anti-viral activity of antibodies to a filovirus...
  24. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
    Dennis Burton; Fiscal Year: 2000
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  25. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPPL-SCID
    Dennis Burton; Fiscal Year: 1999
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  26. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 1993
    ..The research will provide opportunities to explore the mechanism(s) responsible for virus neutralization and some of the rules governing antibody recognition of viral antigens...
  27. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2002
    DESCRIPTION: (Adapted from the Investigator's abstract): this is a new application from Dr. Dennis Burton to study the anti-viral activity of antibodies to a filovirus...
  28. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2002
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  29. NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES
    Dennis Burton; Fiscal Year: 2004
    ..To examine the impact of passive immunization in immunoprophylaxis and immunotherapy of a smallpox-like disease in a non-human primate model, we will use an experimental model of monkeypox virus infection ..
  30. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2004
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. ..
  31. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2004
    DESCRIPTION: (Adapted from the Investigator's abstract): this is a new application from Dr. Dennis Burton to study the anti-viral activity of antibodies to a filovirus...
  32. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2004
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  33. VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES
    Dennis Burton; Fiscal Year: 2004
    ..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..
  34. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2003
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. ..
  35. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2003
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  36. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2003
    DESCRIPTION: (Adapted from the Investigator's abstract): this is a new application from Dr. Dennis Burton to study the anti-viral activity of antibodies to a filovirus...
  37. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis R Burton; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: An optimal HIV vaccine will likely elicit broadly neutralizing antibodies. This application seeks to understand broad neutralization at the molecular level to permit the design of such a vaccine. ..